| # | Drug | Count |
|---|---|---|
| 0 | METHOTREXATE SODIUM | 37 |
| 1 | METHOTREXATE | 33 |
| 2 | DUPILUMAB | 23 |
| 3 | ADALIMUMAB | 21 |
| 4 | CERTOLIZUMAB PEGOL | 17 |
| 5 | PREDNISONE | 14 |
| 6 | UPADACITINIB | 14 |
| 7 | INFLIXIMAB | 13 |
| 8 | RITUXIMAB | 12 |
| 9 | SECUKINUMAB | 12 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BARICITINIB | 8 | 0.0026 |
| 1 | MOGAMULIZUMAB-KPKC | 2 | 0.0015 |
| 2 | BRODALUMAB | 2 | 0.0010 |
| 3 | BEXAROTENE | 1 | 0.0008 |
| 4 | WHITE PETROLATUM | 1 | 0.0007 |
| 5 | TALIMOGENE LAHERPAREPVEC | 1 | 0.0006 |
| 6 | ROMIDEPSIN | 1 | 0.0006 |
| 7 | POLATUZUMAB VEDOTIN | 5 | 0.0005 |
| 8 | BETAMETHASONE DIPROPIONATE | 3 | 0.0004 |
| 9 | ACITRETIN | 2 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Chemokine Receptor Type 4 Interaction [EPC] | 2 | 0.0015 |
| 1 | Interleukin-5 Antagonist [EPC] | 1 | 0.0015 |
| 2 | Interleukin-17 Receptor A Antagonist [EPC] | 2 | 0.0010 |
| 3 | Interleukin-17A Antagonist [EPC] | 17 | 0.0005 |
| 4 | CD30-directed Immunoconjugate [EPC] | 4 | 0.0004 |
| 5 | Histone Deacetylase Inhibitor [EPC] | 1 | 0.0003 |
| 6 | Bispecific CD20-directed CD3 T Cell Engager [EPC] | 1 | 0.0002 |
| 7 | Janus Kinase Inhibitor [EPC] | 25 | 0.0002 |
| 8 | Dopamine-2 Receptor Antagonist [EPC] | 1 | 0.0001 |
| 9 | CD19-directed Chimeric Antigen Receptor [EPC] | 1 | 0.0001 |